Mike Dudley has served as chief executive officer since the company’s inception in 2018, where he led the Series A financing for Qpex and acquisition of the preclinical programs from The Medicines Company.
Mike has more than 40 years of experience in anti-infective research, development and commercialization. He has overseen R&D and regulatory approval of multiple anti-infectives, including most recently vaborbactam, which progressed from discovery to FDA approval in less than eight years. He was chief scientific officer of Rempex Pharmaceuticals, Inc. when it was acquired by The Medicines Company, where he remained and became co-leader of the infectious disease business unit. He has led negotiations for multiple public-private partnerships, including Biomedical Advanced Research and Development Authority (BARDA) and the Innovative Medicines Initiative (IMI), for over $190 million to advance the development of antimicrobial agents in the U.S. and Europe. Before Rempex, Mike held leadership positions of increasing responsibility at Mpex Pharmaceuticals, Diversa Corp. and Microcide Pharmaceuticals. He is a fellow of the Infectious Diseases Society of America (FIDSA).
Prior to his career in industry, Mike held academic appointments at the University of Rhode Island College of Pharmacy and Brown University School of Medicine in Providence, Rhode Island. He has published more than 160 scientific papers and book chapters on the discovery, preclinical/clinical evaluation and use of anti-infectives. Mike completed undergraduate work in biology at Pepperdine University in Malibu, California. He earned a Doctor of Pharmacy and completed his residency at the University of California, San Francisco (UCSF). Mike completed a fellowship in infectious disease at Hartford Hospital in Hartford, Connecticut.
